other · Healthcare · Biotechnology
PHVS
33.65-0.33 -0.96%Past year
Loading chart…
Loading financials…
Company snapshot
- Ticker
- PHVS
- Exchange
- NMS
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.32B
- Employees
- 134
- Currency
- USD
- Website
- https://pharvaris.com
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3,…
Latest coverage
No coverage yet — articles appear here automatically as press releases are published.
Related other stocks
Quotes & data
Follow Pharvaris N.V. (PHVS) across major market-data sources.